SCHEDULE: FMR LLC Reports 7% Stake in Charles River Labs

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Charles River Laboratories International Inc. common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have reported beneficial ownership of 3,456,244.72 shares of Charles River Laboratories International Inc. common stock.
• This holding represents 7.0% of the class of securities as of March 31, 2026.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
• The filing indicates that while FMR LLC has sole voting power over 3,423,033.36 shares, the aggregate beneficial ownership is 3,456,244.72 shares with sole dispositive power.
• The filing is made under Rule 13d-1(b) of the Securities Exchange Act of 1934.
• Several subsidiaries of FMR LLC, including FIAM LLC, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, are identified as entities that beneficially own shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports existing beneficial ownership and does not contain new operational or financial performance data that would typically influence sentiment.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant ownership stake of 7.0% in Charles River Laboratories International Inc., indicating continued investment interest.
• The reporting entities (FMR LLC and its subsidiaries) possess sole dispositive power over the reported shares, suggesting direct control over these holdings.

Risks

• The filing does not explicitly detail any risks associated with the investment or the company itself.

Future Outlook

This filing is a snapshot of beneficial ownership as of a specific date and does not contain forward-looking statements or guidance regarding future performance of Charles River Laboratories International Inc.

Management Comments

• FMR LLC and Abigail P. Johnson, through authorized representatives, certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson indicates a significant institutional holding in Charles River Laboratories International Inc., a key player in the contract research organization (CRO) and drug development services sector. Such filings often signal sustained institutional confidence or a strategic allocation of capital within the life sciences industry.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can influence market perception and potentially stock liquidity.
• Management of Charles River Laboratories International Inc.: The presence of a large institutional holder like FMR LLC may lead to increased engagement on corporate governance and strategic matters.
• Competitors: The filing does not directly impact competitors but highlights the ongoing investment activity within the life sciences sector.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold and potentially manage their beneficial ownership of Charles River Laboratories International Inc. common stock.
• Future filings will be made if there are material changes in beneficial ownership.

Key Dates

Keywords

Charles River Labs, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment Company, Holding Company, Common Stock, SEC Filing, Securities Exchange Act